Abstract Views :200 |
PDF Views:0
Authors
Affiliations
1 Dr. Balabhai Nanavati Hospital, IN
2 Trucare Pharma Pvt. Ltd, First Floor D’Mart Bldg, Goregaon - Mulund Link Rd, Mulund West, Mumbai - 400080, IN
3 Abbott Truecare, IN
4 Medical Services, IN
5 Medical Services, Abbott Healthcare, IN
Source
The Indian Practitioner, Vol 66, No 4 (2013), Pagination: 203-208
Abstract
Objectives: The objective of this study was to investigate the in vitro activity of Tigimax (Tigecycline) against multidrug-resistant Acinetobacter baumannii and other common bacterial isolates from abdominal and skin and soft tissue infections. Methods: Total 102 samples from abdominal and skin and soft tissue infections were studied for the activity of Tigimax (Tigecycline) against isolations of one or more organisms like Acinetobacter spp, E.coli, methicillin resistant Staphylococcus aureus (MRSA), and Klebsiella spp. Antimicrobial susceptibility was done by disc diffusion method as per the Clinical and Laboratory Standards Institute (CLSI) guidelines using the Muller-Hinton agar (Difco, USA) and antimicrobial discs (Oxoid, UK and Hi-Media, Mumbai). Results: Out of 102 samples, 52 were Acinetobacter spp. isolates, 20 were E.coli, 20 were Klebsiella spp. and 10 isolates were MRSA. Out of 52 Acinetobacter spp. isolates 44 (84.6%) found sensitive to Tigimax (Tigecycline), and 8 (15.4%) found resistant. Out of 20 E. coli isolates 19 (95%) were sensitive to Tigimax (Tigecycline) and 1 (5%) was resistant. In all Klebsiella (20) and MRSA (10) samples all were sensitive to Tigimax (Tigecycline). Conclusions: Tigimax (Tigecycline) has shown considerable in-vitro activity against resistant species like Acinetobacter spp., E.coli, MRSA and Klebsiella spp.
